PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses. PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PJT | PJT Partners Inc. | 2026-03-03 12:09:18 | 145.83 | -2.16 | -1.46 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PJT | 0001626115 | PJT Partners Inc. | US69343T1079 | 549300W3WBEQUBKYTN87 | 364797143 | NYSE | 6282 | Investment Advice | 1231 | DE | 280 PARK AVENUE | NEW YORK | NY | 10017 | UNITED STATES | US | 212-364-7800 | 280 PARK AVENUE, NEW YORK, NY, 10017 | 280 PARK AVENUE, NEW YORK, NY, 10017 | PJT Partners Inc. | Investment banking | 2015 | — | 1,143 | http://pjtpartners.com/ | 2,500,000,000 | — | 24,800,541 | PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses. PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn. | 2026-02-26 16:32:20 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 3,900,000,000 | 1,400,000,000 | 56 | — | — | — |
| 2024 | 2,500,000,000 | 900,000,000 | 56.25 | — | — | — |
| 2023 | 1,600,000,000 | -100,000,000 | -5.8824 | — | — | — |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| David A. Travin | General Counsel | 2024 | 500,000 | 1,309,600 | 1,178,400 | — | — | 2,988,000 |
| Helen T. Meates | Chief Financial Officer | 2024 | 1,000,000 | 1,847,700 | 1,640,300 | — | — | 4,488,000 |
| Paul J. Taubman | CEO, Chairman | 2024 | 1,000,000 | 0 | 0 | — | — | 1,000,000 |
| Paul J. Taubman | CEO, Chairman | 2023 | 1,000,000 | 0 | 0 | — | — | 1,000,000 |
| David A. Travin | General Counsel | 2023 | 500,000 | 1,071,500 | 666,500 | — | — | 2,238,000 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 1,224 |
| 2024 | 1,143 |
| 2023 | 1,012 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 1,713,671,000 | 1,493,177,000 | 1,153,182,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | — | — | — |
| Operating Expenses | 1,370,752,000 | 1,222,608,000 | 975,573,000 |
| Operating Income | — | — | — |
| Net Income | 180,115,000 | 134,393,000 | 81,799,000 |
| Earnings Per Share Basic | 7 | 5.28 | 3.24 |
| Earnings Per Share Diluted | 6.68 | 4.92 | 3.12 |
| Weighted Average Shares Outstanding Basic | 25,723,840 | 25,454,445 | 25,255,327 |
| Weighted Average Shares Outstanding Diluted | 28,610,263 | 44,105,131 | 41,882,034 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 538,858,000 | 483,877,000 | 355,543,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 404,322,000 | 320,783,000 | 263,529,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | — | — | — |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 61,042,000 | 22,137,000 | 25,901,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | — | — | — |
| Total Assets | 1,843,250,000 | 1,635,334,000 | 1,434,978,000 |
| Accounts Payable | — | — | — |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | — | — | — |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | 834,207,000 | 733,691,000 | 573,814,000 |
| Common Stock | 360,000 | 340,000 | 324,000 |
| Retained Earnings | 384,187,000 | 228,594,000 | 118,332,000 |
| Accumulated Other Comprehensive Income | 2,825,000 | -1,661,000 | -467,000 |
| Total Shareholders Equity | 308,247,000 | 187,013,000 | 244,669,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 13,343,000 | 12,799,000 | 14,047,000 |
| Share Based Compensation Expense | 234,344,000 | 209,185,000 | 178,535,000 |
| Other Non Cash Income Expense | 3,930,000 | 1,888,000 | 935,000 |
| Change In Accounts Receivable | 75,854,000 | 55,920,000 | -51,904,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -5,373,000 | -11,031,000 | 33,515,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 526,298,000 | 530,950,000 | 441,534,000 |
| Purchases Of Marketable Securities | 182,393,000 | 369,988,000 | 328,767,000 |
| Sales Of Marketable Securities | 199,709,000 | 392,074,000 | 298,348,000 |
| Acquisition Of Property Plant And Equipment | 45,861,000 | 3,298,000 | 3,927,000 |
| Acquisition Of Business | 0 | 10,727,000 | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -28,545,000 | 8,061,000 | -34,346,000 |
| Tax Withholding For Share Based Compensation | 54,882,000 | 37,477,000 | 19,406,000 |
| Payments Of Dividends | 24,522,000 | 24,131,000 | 24,436,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 195,223,000 | 235,104,000 | 116,738,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 0 | 15,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -453,792,000 | -408,684,000 | -228,077,000 |
| Change In Cash | 54,981,000 | 128,334,000 | 182,308,000 |
| Cash At End Of Period | 538,858,000 | 483,877,000 | 355,543,000 |
| Income Taxes Paid | 44,417,000 | 36,082,000 | 23,288,000 |
| Interest Paid | 0 | 0 | 20,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 7 | 5.28 | 3.24 |
| Price To Earnings Ratio | 23.8857 | 29.8883 | 31.4414 |
| Earnings Growth Rate | 32.5758 | 62.963 | -10.2493 |
| Price Earnings To Growth Ratio | 0.7332 | 0.4747 | -3.0677 |
| Book Value Per Share | 39.226 | 35.4218 | 34.0983 |
| Price To Book Ratio | 4.2625 | 4.4552 | 2.9875 |
| Ebitda | 237,875,000 | 183,274,000 | 119,134,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | 0.0057 | 0.006 | 0.0095 |
| Dividend Payout Ratio | 0.1361 | 0.1796 | 0.2987 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 52,248,000 | 9,035,000 | 9,255,000 |
| Free Cash Flow | 474,050,000 | 521,915,000 | 432,279,000 |
| Return On Equity | 0.5843 | 0.7186 | 0.3343 |
| One Year Beta | 1.0031 | 1.2671 | 0.6868 |
| Three Year Beta | 0.9839 | 0.7891 | 0.7647 |
| Five Year Beta | 0.8793 | 1.0088 | 0.9991 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Meates Helen T | Chief Financial Officer | 2026-02-09 | 10,547 | A | 201,345 |
| Lee Ji-Yeun | Managing Partner | 2026-02-09 | 14,613 | A | 699,849 |
| Travin David Adam | General Counsel | 2026-02-09 | 6,823 | A | 20,243 |
| Travin David Adam | General Counsel | 2026-02-05 | 8,264 | D | 13,420 |
| Taubman Paul J | Director, Chairman and CEO | 2026-02-05 | 36,000 | D | 5,424,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Invesco Ltd. | 2025-12-31 | 89,595,290 | 535,857 | 167.2 |
| NewEdge Advisors, LLC | 2025-12-31 | 542 | 3 | 180.6667 |
| State of Tennessee, Department of Treasury | 2025-12-31 | 936,439 | 5,412 | 173.0301 |
| MACKENZIE FINANCIAL CORP | 2025-12-31 | 242,504 | 1,432 | 169.3464 |
| RAYMOND JAMES FINANCIAL INC | 2025-12-31 | 73,987,245 | 437,281 | 169.1984 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCMX | 31 | 5,183.2 | 0.0614 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYAKX | 31 | 5,183.2 | 0.0614 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYMKX | 31 | 5,183.2 | 0.0614 |
| RYDEX DYNAMIC FUNDS | 2025-12-31 | H-Class Shares | RYRSX | 114 | 19,060.8 | 0.0349 |
| RYDEX DYNAMIC FUNDS | 2025-12-31 | C-Class Shares | RYRLX | 114 | 19,060.8 | 0.0349 |